No abstract available
MeSH terms
-
Angiogenesis Inhibitors / economics
-
Angiogenesis Inhibitors / therapeutic use
-
Antibodies, Monoclonal, Humanized / economics
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Aptamers, Nucleotide / economics
-
Aptamers, Nucleotide / therapeutic use
-
Bevacizumab
-
Comparative Effectiveness Research
-
Diabetic Retinopathy / complications*
-
Diabetic Retinopathy / drug therapy*
-
Drug Costs*
-
Evidence-Based Medicine
-
Humans
-
Intravitreal Injections
-
Macular Edema / drug therapy*
-
Macular Edema / etiology*
-
Off-Label Use*
-
Ranibizumab
-
Receptors, Vascular Endothelial Growth Factor
-
Recombinant Fusion Proteins / economics
-
Recombinant Fusion Proteins / therapeutic use
-
United States
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal, Humanized
-
Aptamers, Nucleotide
-
Recombinant Fusion Proteins
-
Vascular Endothelial Growth Factor A
-
aflibercept
-
pegaptanib
-
Bevacizumab
-
Receptors, Vascular Endothelial Growth Factor
-
Ranibizumab